Abstract
PALB2 has been recently identified as breast cancer susceptibility gene in western populations. To investigate the contribution of PALB2 mutations to Chinese non-BRCA1/BRCA2 hereditary breast cancer, we screened all coding exons and intron-exon boundaries of PALB2 in 360 Chinese women with early-onset breast cancer or affected relatives from five breast disease clinical centers in China by utilizing PCR-DHPLC and DNA sequencing analysis. Some genetic variants identified in the cases were then studied in 864 normal controls with no personal or family history of breast cancer. Two protein-truncating PALB2 mutations, 751C>T and 1050_1051delAAinsTCT, were identified in three separate families, and 751C>T was a recurrent mutation. Neither of them, however, were present in the controls (P = 0.025). All the truncating mutations occured in exon 4 of PALB2, and there were still three unclassified variants were detected in the same fragment. We found that exon 4 accounted for 44.1% (15/34) of the person-times carrying with any variant in our study. PALB2 mutations were responsible for approximately 1% of Chinese women with early-onset breast cancer and affected relatives. Our results suggested that a detection of exon 4 before the assay of the whole PALB2 gene might be a cost-effective approach to the screening of Chinese population.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Li WF, Hu Z, Rao NY et al. (2007) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat doi:10.1007/s10549-007-9708-3 (in press)
Xia B, Sheng Q, Nakanishi K, Ohashi A et al (2007) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22:719–729
Simpson S (2007) PALB2-new breast-cancer susceptibility gene. Lancet Oncol 8(2):105
Xia B, Dorsman JC, Ameziane N et al (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39:159–161
Reid S, Schindler D, Hanenberg H et al (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39:162–164
Howlett NG (2007) Fanconi anemia: Fanconi anemia, breast and embryonal cancer risk revisited. Eur J Hum Genet 15:715–7
Walsh T, King MC (2007) Ten genes for inherited breast cancer. Cancer Cell 11:103–105
Offit K (2006) BRCA mutation frequency and penetrance: new data, old debate. J Natl Cancer Inst 98:1675–1677
Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165–167
García MJ, Fernández V, Osorio A et al. (2008) Analysis of FANCB and FANCN/PALB2 Fanconi Anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat doi:10.1007/s10549–008-9945-0 (in press)
Foulkes WD, Ghadirian P, Akbari MR et al (2007) Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French–Canadian women. Breast Cancer Res 9:R83
Erkko H, Xia B, Nikkilä J et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446:316–319
Tischkowitz M, Xia B, Sabbaghian N et al (2007) Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA 104:6788–6793
Offit K (2000) Are BRCA1- and BRCA2-associated breast cancers different? J Clin Oncol 18:104–106
Phillips KA (2000) Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18:107–112
Armes JE, Venter DJ (2002) The pathology of inherited breast cancer. Pathology 34:309–314
Klein B, Weirich G, Brauch H (2001) DHPLC-based germline mutation screening in the analysis of the VHL tumor suppressor gene: usefulness and limitations. Hum Genet 108:376–384
Xiao W, Oefner PJ (2001) Denaturing high-performance liquid chromatography: a review. Hum Mutat 17:439–474
Song CG, Hu Z, Wu J et al (2006) The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer. J Cancer Res Clin Oncol 32:617–626
Hu Z, Wu J, Liu CH et al (2003) The analysis of BRCA1 mutations in eastern Chinese patients with early onset breast cancer and affected relatives. Hum Mutat 22:104
NCBI [http://www.ncbi.nlm.nih.gov/]
Acknowledgments
The authors thank the family members for their willingness to cooperate with our study. This research was supported in part by the grants from the National Basic Research Program of China (2006CB910501), National Natural Science Foundation of China (30371580, 30572109); Shanghai Science and Technology Committee (03J14019, 06DJ14004, 06DZ19504)
Author information
Authors and Affiliations
Corresponding author
Additional information
A-Yong Cao, Juan Huang, and Zhen Hu contributed equally to this work.
Rights and permissions
About this article
Cite this article
Cao, AY., Huang, J., Hu, Z. et al. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 114, 457–462 (2009). https://doi.org/10.1007/s10549-008-0036-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-008-0036-z